ISPOR CEO NANCY BERG NAMED A PHARMAVOICE 100

Published Aug 8, 2016
Annual List Recognizes Inspirational Individuals Who Have Made Positive Contributions to the Life Sciences Industry  Princeton, NJ—August 8, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that its Chief Executive Officer Nancy Berg has been named a 2016 PharmaVOICE 100. The PharmaVOICE 100 was established twelve years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life sciences industry. The PharmaVOICE 100 honorees represent a broad cross-section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors. This diverse group of individuals also represents a wide variety of functional areas ranging from the clinic to the C-suite. Berg assumed the role of CEO and Executive Director of ISPOR, a non-profit organization based in central New Jersey, in 2014. Over the past 20 years, ISPOR has become a the leading global scientific and educational organization for health economics and outcomes research (HEOR). PharmaVOICE highlights Berg’s forward-thinking and strategic leadership as a key to positioning ISPOR as a global leader in HEOR. "This must-read issue has become one of the most-anticipated and highly regarded publications of the year, and it is our great pleasure to showcase the 100 men and women who are demonstrating inspired leadership, innovating across the ecosystem, creating transformative change, disrupting the status quo, and building relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients," said Taren Grom, Editor and Co-founder of PharmaVOICE. “I am deeply honored to be among the PharmaVOICE 100 leaders recognized this year,” noted Berg. “ISPOR’s members play an essential role in improving health care by bringing research excellence into the everyday health decisions that impact patients’ lives. It is a true honor to serve the Society at a time when the importance of HEOR has never been greater.”

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×